Novotná J, Andrysek O, Kobilková J, Laurová L
Neoplasma. 1983;30(2):245-50.
The authors report their results of treatment in patients with ovarian carcinoma (stages III and IV, FIGO classification) with the cytostatic Penberol (cis-beta-4-pentoxybenzoyl-beta-bromoacrylic acid), synthesized at the Research Institute for Pharmacy and Biochemistry in Prague. The present communication links on the paper published in 1980. Out of 20 patients treated with Penberol, 11 have responded by a complete remission persisting for 8-55 months; in five of them the remission has not finished as yet. Both in the experiment and in the clinic the behavior of Penberol differs from that of classical cytostatics, and the observations evaluated so far attest to antitumor activity based on inhibition of the cell energetic metabolism.
作者报告了用细胞抑制剂Penberol（顺式-β-4-戊氧基苯甲酰-β-溴丙烯酸）治疗卵巢癌（国际妇产科联盟（FIGO）分类的III期和IV期）患者的结果。该细胞抑制剂由布拉格的药学与生物化学研究所合成。本报告基于1980年发表的论文。在接受Penberol治疗的20例患者中，11例获得完全缓解，缓解持续时间为8至55个月；其中5例缓解仍未结束。在实验和临床中，Penberol的表现均与传统细胞抑制剂不同，迄今为止的观察结果证实其抗肿瘤活性基于对细胞能量代谢的抑制。
